Zhao Bennan, Kang Jun, Du Qing, Liu Dafeng
The First Ward of Internal Medicine, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China.
The Second Ward of ICU, Public Health Clinical Center of Chengdu, Chengdu, People's Republic of China.
Int J Gen Med. 2025 Apr 8;18:2009-2019. doi: 10.2147/IJGM.S517920. eCollection 2025.
There has been a lack of comprehensive studies on the long-term observation of laboratory values following the administration of SARS-CoV-2 vaccines. The objective of this study is to assess the long-term impact of inactivated SARS-CoV-2 vaccines on coagulation function and other health indicators.
We enrolled residents of Chengdu who consented to receive inactivated SARS-CoV-2 vaccines, categorizing them into two groups: healthy donors (n=40) and survivors of COVID-19 infection (n=34), based on their SARS-CoV-2 infection status prior to vaccination. Blood samples from the subjects were collected at specific intervals following vaccination.
The levels of Fibronectin (FN) increased significantly in both healthy donors and survivors of COVID-19 infection after receiving two doses of the inactivated SARS-CoV-2 vaccine (both P < 0.001), and there was no statistically significant difference in the degree of FN increase between the two groups (153.05 ± 77.19 mg/L vs 172.32±90.42 mg/L, P=0.326). The rate of elevated FN levels was significantly higher six months after vaccination compared to the rate before vaccination, both in healthy donors (85.0% vs 5.0%, P<0.001) and in survivors of COVID-19 infection (94.1% vs 29.4%, P<0.001). Additionally, the levels of FN in healthy donors further increased six months after receiving a booster dose of the inactivated vaccine compared to pre-booster levels (569.90±119.44 mg/L vs 467.35±62.04 mg/L, P < 0.001).
The study indicates that serum FN levels increased significantly following the administration of the inactivated SARS-CoV-2 vaccine, and these elevated FN levels may persist for more than six months. However, it remains unclear whether this increase could result in any adverse effects.
对于接种新型冠状病毒2(SARS-CoV-2)疫苗后实验室检查值的长期观察,一直缺乏全面的研究。本研究的目的是评估灭活SARS-CoV-2疫苗对凝血功能和其他健康指标的长期影响。
我们招募了同意接种灭活SARS-CoV-2疫苗的成都居民,根据他们接种疫苗前的SARS-CoV-2感染状况将其分为两组:健康供者(n = 40)和新型冠状病毒肺炎(COVID-19)感染幸存者(n = 34)。在接种疫苗后的特定时间间隔采集受试者的血样。
健康供者和COVID-19感染幸存者在接种两剂灭活SARS-CoV-2疫苗后,纤连蛋白(FN)水平均显著升高(均P < 0.001),两组间FN升高程度无统计学显著差异(153.05±77.19mg/L vs 172.32±90.42mg/L,P = 0.326)。接种疫苗六个月后,健康供者(85.0% vs 5.0%,P < 0.001)和COVID-19感染幸存者(94.1% vs 29.4%,P < 0.001)中FN水平升高的比例均显著高于接种疫苗前。此外,健康供者在接种一剂灭活疫苗加强针六个月后,FN水平相较于加强针前进一步升高(569.90±119.44mg/L vs 467.35±62.04mg/L,P < 0.00